SCP-776 is under clinical development by Silver Creek Pharmaceuticals and currently in Phase II for Acute Ischemic Stroke. According to GlobalData, Phase II drugs for Acute Ischemic Stroke have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SCP-776’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SCP-776 overview

SCP-776 is under development for the treatment of congestive heart failure and acute ischemic stroke. It is administered through parenteral and intravenous route. The therapeutic candidates act by targeting the insulin-like growth factor-1 receptor. The therapeutic candidates comprise of protein which is modified by fusing them to insulin-like growth factor-1 and Annexin A5 (AnxV).

Silver Creek Pharmaceuticals overview

Silver Creek Pharmaceuticals (Silver Creek), a subsidiary of Merrimack Pharmaceuticals Inc is a biotechnology company that discovers and develops targeted protein therapeutics for the treatment of cardiovascular diseases. The company offers medicines to repair and regenerate functional tissue in the areas of heart disease, kidney disease and neurological disorders, among others. The company designs smart growth factors technology (SGF), a new platform of bio-therapeutics with improved pharmacodynamics, pharmacokinetics and accumulation, improving drug-like properties to optimize as cardioprotective therapeutics. The company’s SGF technology offers computational modeling, protein engineering, in-vivo testing and in-vitro screening. Silver Creek is headquartered in San Francisco, California, the US.

For a complete picture of SCP-776’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.